Recent studies have suggested a connection between mitochondrial DNA (mtDNA) and autism. At MNG Laboratories™, we strive to offer a comprehensive portfolio of tests to provide your patients with the answers they need. Our philosophy of offering mtDNA sequencing and deletion analysis to many of our sequencing panels has resulted in a 15.1% increase in the diagnostic sensitivity.
As part of our continued promise to offer the most technically advanced and clinically informative testing in the market, we are proud to announce the addition of mtDNA sequencing and deletion analysis to our Comprehensive Intellectual Disability/Autism panel at no additional cost.
The MNG Neurobehavioral disorder portfolio encompasses a variety of rare genetic neurological disorders, including those related to cognition, neurodevelopment, and neurodegeneration, and this exciting addition to our robust test offerings further supports the quality delivered via our Neurogenetic Answers™ reporting platform.
1) Varga, N., Pentelényi, K., Balicza, P., Gézsi, A., Reményi, V., Hársfalvi, V., . . . Molnár, M. (2018). Mitochondrial dysfunction and autism: Comprehensive genetic analyses of children with autism and mtDNA deletion. Behavioral and Brain Functions : BBF, 14(1), 4.
2) Chalkia D, Singh LN, Leipzig J, et al. Association Between Mitochondrial DNA Haplogroup Variation and Autism Spectrum Disorders. JAMA Psychiatry. 2017;74(11):1161–1168. doi:10.1001/jamapsychiatry.2017.2604
Effective July 27, 2020 the MNG amino acid assays, Test Codes MET01, MET02, and MET03 will be performed by our Parent company, LabCorp, in its Burlington, NC laboratory.
MNG is excited to announce the launch of 15 new next-generation sequencing (NGS) panels. In an effort to meet the needs of our clients, we are introducing a Comprehensive Hearing Loss panel and a Comprehensive Vision Loss & Eye Disorders panel, both including mtDNA analysis.
Due to a manufacturer reagent change, MNG will discontinue testing for Folate Receptor Antibodies.